IMI is welcoming all stakeholders in health and medicines R&D to join the Stakeholder Forum on 18 and 19 October 2017: This includes policy-makers, academics and researchers, the pharmaceutical industry, other sectors with an interest in health research, SMEs and mid-sized enterprises, patient representatives and regulators, representatives of other public-private partnerships and research-funding organizations.
Patricia van Dijck, Project Leader of HARMONY and Director Healthcare Systems Solutions, Novartis, participated in the Patient Forum.
In IMI’s public-private open innovation model, patients are the ultimate recipients of IMI’s R&D efforts, and are an invaluable partner in research. The goal of this parallel track will be to further the discussion on what are the most meaningful models of patient collaboration in order for patients’ voices to be heard. Read more >>
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
